EW Healthcare Partners, L.P. - 01 Sep 2023 Form 4/A - Amendment Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Source evidence Original filing metadata and source links for verification. 6 source fields
SEC form
4/A - Amendment
Accepted by SEC
06 Sep 2023, 19:10:14 UTC
Original report date
06 Sep 2023
Prior SEC filing
01 Sep 2023
Next SEC filing
12 Sep 2023
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
EW Healthcare Partners, L.P.; By Essex Woodlands Fund IX-GP, L.P., its General Partner; By Essex Woodlands IX, LLC, its General Partner; By Ronald Eastman, Manager; ByGregory L. Hill, Attorney-in-Fact, /s/ Gregory L....
Open signature details
EW Healthcare Partners, L.P.; By Essex Woodlands Fund IX-GP, L.P., its General Partner; By Essex Woodlands IX, LLC, its General Partner; By Ronald Eastman, Manager; ByGregory L. Hill, Attorney-in-Fact, /s/ Gregory L. Hill

Key filing fact

EW Healthcare Partners, L.P. filed Form 4/A - Amendment for EyePoint Pharmaceuticals, Inc. (EYPT) on 06 Sep 2023.

Key facts

  • This page summarizes EW Healthcare Partners, L.P.'s Form 4/A - Amendment filing for EyePoint Pharmaceuticals, Inc. (EYPT).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 06 Sep 2023, 19:10.

Change

  • Previous filing in this sequence was filed on 01 Sep 2023.
  • Current net transaction value: -$197,982.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EYPT transaction

Common Stock, $0.001 par value

Sale

Transaction value
$197,982
Shares
-20,000
Change %
-0.57%
Price
$9.90
Shares after
3,490,921
Date
01 Sep 2023
Ownership
See Footnotes
Footnotes
F1, F2, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

EW Healthcare Partners, L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

The share total shown above is the aggregate amount of shares of Common Stock sold by EW Healthcare Partners, L.P. ("EWHP") and EW Healthcare Partners-A, L.P. ("EWHP-A") on the date set forth above. EWHP sold 19,226 shares of the amount shown above, and EWHP-A sold 774 shares of the amount shown above. EWHP now holds a total of 3,355,921 shares of Common Stock of the Issuer and EWHP-A now holds a total of 135,000 shares of Common Stock of the Issuer.

Footnote F2

Price is the volume weighted average selling price of all sales by the Reporting Persons on the transaction date within a one dollar range. Actual prices ranged from $9.73 to $10.11. The Reporting Persons hereby undertake to provide upon request of the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Footnote F3

Essex Woodlands Fund IX-GP, L.P. (the "EW Fund IX GP"), is the general partner of each of EW Healthcare Partners, L.P. ("EWHP") and EW Healthcare Partners-A, L.P. ("EWHP-A" and together with EWHP, the "EWHP Funds"). Essex Woodlands IX, LLC (the "General Partner") is the general partner of EW Fund IX GP. The General Partner holds sole voting and dispositive power over the shares held by each of the EWHP Funds (the "Shares''). The managers of the General Partner are Martin P. Sutter, Scott Barry, Ron Eastman, Petri Vainio and Steve Wiggins (collectively, the ''Managers'') and may exercise voting and investment control over the Shares only by majority action of the Managers. Each individual Manager, the EW Fund IX GP and the General Partner disclaims ownership over the Shares except to the extent of his or its respective pecuniary interest therein.

SEC remarks

This Amended Form 4 is being filed to correct the Form 4 filed regarding this reported transaction to reflect the fact that the Reporting Persons are no longer subject to the Section 16 reporting obligations.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .